Cancer Radiotherapie最新文献

{"title":"Role of radiotherapy in the management of anal canal cancer: Recommendations of the Société française de radiothérapie oncologique","authors":"Charles Raynaud ,&nbsp;Maria Jolnerovski ,&nbsp;Claire Lemanski ,&nbsp;Benjamin Schipman ,&nbsp;Laurence Moureau-Zabotto ,&nbsp;Igor Bessières ,&nbsp;Florence Huguet ,&nbsp;Véronique Vendrely","doi":"10.1016/j.canrad.2025.104770","DOIUrl":"10.1016/j.canrad.2025.104770","url":null,"abstract":"<div><div>We present the updated recommendations from the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology) regarding the use of external beam radiotherapy and brachytherapy in the management of anal cancer. Anal cancer is a rare malignancy with an increasing incidence, largely due to the high prevalence of Human papillomavirus infection. It primarily affects females over 65<!--> <!-->years of age. The most common histological type is squamous cell carcinoma. The standard treatment involves a combination of intensity-modulated radiotherapy and concurrent chemotherapy with 5-fluorouracil (or capecitabine) and mitomycin. A localized boost dose to the tumour can be delivered either by external beam radiotherapy or brachytherapy. Recent studies have demonstrated that intensity-modulated radiotherapy helps avoid treatment interruptions, which are considered detrimental to efficacy. However, while radiotherapy achieves good outcomes for T1-T2 tumours without nodal involvement, T3-T4 stages or tumours with nodal involvement are associated with a poorer prognosis. Therefore, concomitant chemotherapy (5-fluorouracil or capecitabine with mitomycin) is recommended for tumours greater than 3<!--> <!-->cm or those with nodal invasion. This approach remains a topic of debate for early-stage tumours. Target volumes, organs at risk delineation, doses, and fractionation regimens are discussed with respect to the balance between treatment efficacy and toxicity. Follow-up recommendations are provided to ensure early detection of cancer recurrence and late treatment-related side effects.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104770"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy for hypopharynx cancers: 2025 update","authors":"Dylan Bocha ,&nbsp;Julian Biau ,&nbsp;Alexandre Coutte ,&nbsp;Andrès Huertas ,&nbsp;Nolwenn Delaby ,&nbsp;Michel Lapeyre ,&nbsp;Pierre Blanchard ,&nbsp;Yoann Pointreau","doi":"10.1016/j.canrad.2025.104755","DOIUrl":"10.1016/j.canrad.2025.104755","url":null,"abstract":"&lt;div&gt;&lt;div&gt;We present the update of the recommendations of the Société française de radiothérapie oncologique on radiotherapy for hypopharynx. Intensity-modulated radiotherapy is the gold standard treatment for hypopharynx cancers. Early T1 and T2 tumours can be treated by exclusive radiation or surgery followed by postoperative radiation in case of high recurrence risk. For locally advanced tumours requiring total pharyngolaryngectomy (T2 or T3) or with significant lymph nodes involvement, they can be treated by chemoradiation or by induction drugs followed by exclusive radiation. For T4 tumour, surgery must be proposed. Different fractionation schedules are possible: for 35 fractions, the curative dose is 70&lt;!--&gt; &lt;!--&gt;Gy (delivered at 2&lt;!--&gt; &lt;!--&gt;Gy per fraction) and prophylactic doses are 50 to 56&lt;!--&gt; &lt;!--&gt;Gy (delivered at 2&lt;!--&gt; &lt;!--&gt;Gy per fraction in case of sequential radiotherapy or 1.6&lt;!--&gt; &lt;!--&gt;Gy in case of simultaneous integrated boost radiotherapy; for 33 fractions, the curative dose is 69.96&lt;!--&gt; &lt;!--&gt;Gy (delivered at 2.12&lt;!--&gt; &lt;!--&gt;Gy per fraction) and the prophylactic dose is 52.8&lt;!--&gt; &lt;!--&gt;Gy (delivered at 1.6&lt;!--&gt; &lt;!--&gt;Gy per fraction in simultaneous integrated boost radiotherapy or 54&lt;!--&gt; &lt;!--&gt;Gy in 1.64&lt;!--&gt; &lt;!--&gt;Gy per fraction); for 30 fractions, curative dose is 66&lt;!--&gt; &lt;!--&gt;Gy (delivered at 2.2&lt;!--&gt; &lt;!--&gt;Gy per fraction) and prophylactic dose is 54&lt;!--&gt; &lt;!--&gt;Gy (delivered at 1.8&lt;!--&gt; &lt;!--&gt;Gy per fraction in simultaneous integrated boost radiotherapy. Doses over 2&lt;!--&gt; &lt;!--&gt;Gy per fraction can be delivered when chemotherapy is not used regarding potential larynx toxicity. Postoperatively, radiotherapy is used for locally advanced cancer with dose levels based on pathologic criteria, delivering 60 to 66&lt;!--&gt; &lt;!--&gt;Gy for R1 resection and 57.6 to 60&lt;!--&gt; &lt;!--&gt;Gy for complete resection in bed tumour; 50 to 66&lt;!--&gt; &lt;!--&gt;Gy in lymph nodes areas regarding extracapsular spread. Target volume delineation recommendations were based on guidelines cited in this article.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;Nous présentons la mise à jour des recommandations de la Société française de radiothérapie oncologique concernant la radiothérapie du cancer de l’hypopharynx. La radiothérapie conformationnelle avec modulation d’intensité est le traitement de référence pour les cancers de l’hypopharynx. Les tumeurs de stade précoce (T1 et T2) peuvent être traitées soit par irradiation exclusive soit par chirurgie suivie d’une irradiation postopératoire en cas de risque élevé de récidive. Pour les tumeurs localement évoluées nécessitant une pharyngolaryngectomie totale (T2 ou T3) ou avec un envahissement ganglionnaire significatif, elles peuvent être prises en charge d’emblée par une chimioradiothérapie concomitante ou par une chimiothérapie d’induction suivie d’une radiothérapie exclusive. Pour les tumeurs de stade T4, la chirurgie doit être proposée. Différents schémas de fractionnement sont envisageables: en 35 fractions, la dose à visée curative est de 70&lt;!--&gt; ","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104755"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy guidelines for gliomas: 2025 update","authors":"Delphine Antoni ,&nbsp;Emmanuel Mesny ,&nbsp;Osman El Kabbaj ,&nbsp;Charlotte Robert ,&nbsp;Kévin Quintin ,&nbsp;Loïc Feuvret ,&nbsp;Julian Biau ,&nbsp;Julian Jacob","doi":"10.1016/j.canrad.2025.104774","DOIUrl":"10.1016/j.canrad.2025.104774","url":null,"abstract":"<div><div>Gliomas are the most frequent malignant primary brain tumours in adults. The proximity of organs at risk, the infiltrating nature, and the radioresistance of gliomas have to be taken into account in the choice of prescribed dose and technique of radiotherapy. The management of glioma patients is based on clinical factors (age, Karnofsky performance status) and tumour characteristics (histology, molecular biology, tumour location), and strongly depends on available and associated treatments, such as surgery, radiotherapy, and chemotherapy. The knowledge of molecular biomarkers is currently essential; they are increasingly evolving as additional factors that facilitate diagnostics and therapeutic decision-making. We present the update of the recommendations of the Société française de radiothérapie oncologique (the French Society for Radiation Oncology) on the indications and the technical procedures for performing radiotherapy in patients with gliomas.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104774"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reirradiation of prostate, gynaecologic and pelvic tumours, suggestions from the Recommendations Commission of the Société française de radiothérapie oncologique","authors":"Yuedan Zhou ,&nbsp;Alexandre Escande ,&nbsp;David Pasquier ,&nbsp;Cyrus Chargari ,&nbsp;Myriam Ayadi ,&nbsp;Jonathan Khalifa ,&nbsp;Delphine Antoni ,&nbsp;Igor Latorzeff ,&nbsp;Valentine Guimas ,&nbsp;Véronique Vendrely ,&nbsp;Arnaud Beddok ,&nbsp;Stéphane Supiot","doi":"10.1016/j.canrad.2025.104778","DOIUrl":"10.1016/j.canrad.2025.104778","url":null,"abstract":"<div><div>The process of reirradiation in oncology presents a distinctive set of challenges, wherein clinical decision-making is predicated on a delicate balancing act between the efficacy of the treatment and the risk of severe toxicity. Despite the paucity of randomized and prospective data, an increasing number of clinical guidelines encourage its consideration for patients with local or metastatic recurrence. While awaiting dedicated guidance from international scientific societies, the following publication is based on the guidelines and multicentre reflections of the Recommendations Commission of the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology). It addresses key questions related to reirradiation, with a particular focus on prostate, gynaecological and pelvic tumours.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104778"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145607879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumour and normal tissue radiosensitivity: 2025 update","authors":"Ariane Lapierre ,&nbsp;Jeanne Monge-Cadet ,&nbsp;Muriel Brengues ,&nbsp;Igor Bessières ,&nbsp;Laurent Quéro ,&nbsp;Céline Mirjolet ,&nbsp;Olivier Riou","doi":"10.1016/j.canrad.2025.104720","DOIUrl":"10.1016/j.canrad.2025.104720","url":null,"abstract":"<div><div>The personalization of oncology and radiation treatments is becoming increasingly crucial in patient care. Over the past few decades, numerous assays have been developed to predict tumour response and assess the risk of radiation-induced toxicity. These tests have not yet been integrated into routine clinical practice, but recent advances in radiation oncology are paving the way for personalized strategies that consider both tumour recurrence risk and normal tissue reactions. Regarding tumour radiosensitivity prediction, no tests are currently in clinical use, although the radiosensitivity index and Genome-based Model for Adjusting Radiotherapy Dose assays appear to be the most promising, with level II evidence. Development of radiomics has also made it possible to envisage new biomarkers. Prospective studies are ongoing. For normal tissue radiosensitivity prediction, single nucleotide polymorphims in prostate cancer and head and neck cancer patients, and the radiation-induced CD8 T-lymphocyte apoptosis assay for breast and prostate cancers are supported by level I evidence. These tests can be offered prior to the initiation of radiotherapy to tailor treatments based on both tumour and normal tissue radiosensitivity risks.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104720"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145045189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Specific features of clinical research in radiotherapy in France","authors":"Gilles Créhange ,&nbsp;Christophe Hennequin ,&nbsp;Benoît Allignet ,&nbsp;David Azria ,&nbsp;Pierre Blanchard ,&nbsp;Igor Latorzeff ,&nbsp;Véronique Vendrely ,&nbsp;Catherine Dejean ,&nbsp;Laure Parent ,&nbsp;Régis Ferrand ,&nbsp;Yoann Pointreau","doi":"10.1016/j.canrad.2025.104768","DOIUrl":"10.1016/j.canrad.2025.104768","url":null,"abstract":"<div><div>The aim of this article is to present the specifics of clinical research in radiotherapy in France, in order to facilitate the drafting of research protocols. The objectives of research are similar to those of any oncological research: to improve the therapeutic index and, if possible, the results in terms of survival. Phase III trials are still essential, but phase II trials provide interesting information on both the efficacy and tolerability of treatments. The particularities of radiotherapy trials are discussed in terms of inclusion criteria, judgment criteria and therapeutic modalities. The importance of quality control is emphasized. Finally, the difficulties of funding, which is usually academic, are discussed.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104768"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145662741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy for lung metastases","authors":"Antonin Levy ,&nbsp;Marion Tonneau ,&nbsp;Julien Darréon ,&nbsp;Jonathan Khalifa ,&nbsp;Delphine Antoni ,&nbsp;Eivind Blais ,&nbsp;Cécile Le Péchoux ,&nbsp;Delphine Lerouge ,&nbsp;François Lucia ,&nbsp;Alexis Marguerit ,&nbsp;Étienne Martin ,&nbsp;Baptiste Pichon ,&nbsp;Nicolas Pourel ,&nbsp;François-Georges Riet ,&nbsp;Philippe Giraud ,&nbsp;Sébastien Thureau","doi":"10.1016/j.canrad.2025.104760","DOIUrl":"10.1016/j.canrad.2025.104760","url":null,"abstract":"<div><div>Pulmonary metastases are a common site of spread for many cancers, regardless of the primary tumour. While systemic treatments remain the standard of care, local therapies, particularly stereotactic body radiotherapy, have shown promising results in terms of local control and survival in selected patients with oligometastatic disease. This document presents the updated recommendations from the Société française de radiothérapie oncologique (SFRO, French society for radiation oncology) regarding the indications and technical aspects of radiotherapy for intrapulmonary metastases. The focus is on stereotactic body radiotherapy, including patient selection criteria, prescription protocols, treatment planning, respiratory motion management, and organ-at-risk constraints. Alternative approaches, such as moderately hypofractionated palliative radiotherapy, are also discussed for cases where stereotactic body radiotherapy is not feasible. These recommendations aim to guide clinical practice and promote the safe and effective use of high-precision radiotherapy for pulmonary metastases.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104760"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145508525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delineation of organs at risk in radiotherapy and perspectives","authors":"Jordan Eber ,&nbsp;Sophie Bockel ,&nbsp;Delphine Antoni ,&nbsp;Catherine Khamphan ,&nbsp;Georges Noël ,&nbsp;Clara Le Fèvre","doi":"10.1016/j.canrad.2025.104758","DOIUrl":"10.1016/j.canrad.2025.104758","url":null,"abstract":"<div><div>The delineation of organs at risk is fundamental in radiotherapy, ensuring optimal tumour targeting while minimizing toxicity to healthy tissues. Advances in imaging, including MRI-based segmentation and functional imaging, have improved contour precision, while artificial intelligence-assisted autosegmentation enhances efficiency and reproducibility. This article presents updated organs at risk delineation guidelines, incorporating emerging critical structures and refined contouring protocols. Despite technological progress, challenges remain in integrating artificial intelligence-driven tools and functional imaging into routine practice, requiring continued validation and standardization. The future of organs at risk delineation lies in a multidisciplinary approach combining automation, adaptive radiotherapy, and personalized treatment planning to optimize patient safety and long-term outcomes.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104758"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality and safety in radiation oncology: Innovation and beyond","authors":"Nicolas Pourel ,&nbsp;Laure Parent ,&nbsp;Jean-Chirstophe Faivre ,&nbsp;Emma Pellen ,&nbsp;Fabrice Lorchel ,&nbsp;Gianfranco Brusadin","doi":"10.1016/j.canrad.2025.104766","DOIUrl":"10.1016/j.canrad.2025.104766","url":null,"abstract":"<div><div>Quality and risk management systems of French radiotherapy centres are relentlessly mutating in order to cope with regulatory changes and new challenges. In April 2021, the Autorité de sûreté nucléaire (ASN, the French nuclear safety authority) strengthened quality assurance requirements by developing change management, professional licensing processes and peer audit. The certification system of the Haute Autorité de santé (HAS, the French high authority for health) is likewise undergoing significant evolutions with each iteration. These developments emphasize the importance of robust organizational frameworks that are regularly assessed and optimized to address risks, with a strong focus on digital challenges.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104766"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145574989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of radiotherapy in the management of vulvar cancer: Recommendations of the Société française de radiothérapie oncologique, 2025 update","authors":"Cyrus Chargari ,&nbsp;Sophie Renard ,&nbsp;Marie-Adélaïde Ossedat ,&nbsp;Abel Cordoba ,&nbsp;François Lucia ,&nbsp;Adeline Petit ,&nbsp;Sylvain Demontoy ,&nbsp;Isabelle Flandin ,&nbsp;Caroline Lafond ,&nbsp;Anne Ducassou ,&nbsp;Alexandre Escande","doi":"10.1016/j.canrad.2025.104726","DOIUrl":"10.1016/j.canrad.2025.104726","url":null,"abstract":"<div><div>Primary vulvar carcinomas are rare gynaecological cancers, for which surgery is the mainstay of treatment. There is however a major place for external beam radiotherapy in the situation of inoperable locally advanced tumours and/or as adjuvant therapy, when there are risk factors for locoregional relapse. We present the 2025 update of recommendations from the Société française de radiothérapie oncologique on the indications and techniques for radiotherapy in the treatment of primary vulvar cancer.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104726"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145082065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}